| Alzheimer’s disease risk gene CD33 inhibits microglial uptake of amyloid beta A Griciuc, A Serrano-Pozo, AR Parrado, AN Lesinski, CN Asselin, K Mullin, ... Neuron 78 (4), 631-643, 2013 | 1098 | 2013 |
| TREM2 acts downstream of CD33 in modulating microglial pathology in Alzheimer’s disease A Griciuc, S Patel, AN Federico, SH Choi, BJ Innes, MK Oram, ... Neuron 103 (5), 820-835. e7, 2019 | 314 | 2019 |
| Astrocytic interleukin-3 programs microglia and limits Alzheimer’s disease CS McAlpine, J Park, A Griciuc, E Kim, SH Choi, Y Iwamoto, MG Kiss, ... Nature 595 (7869), 701-706, 2021 | 257 | 2021 |
| The role of innate immune genes in Alzheimer's disease A Griciuc, RE Tanzi Current opinion in neurology 34 (2), 228-236, 2021 | 163 | 2021 |
| Gene therapy for Alzheimer’s disease targeting CD33 reduces amyloid beta accumulation and neuroinflammation A Griciuc, AN Federico, J Natasan, AM Forte, D McGinty, H Nguyen, ... Human molecular genetics 29 (17), 2920-2935, 2020 | 103 | 2020 |
| Cromolyn reduces levels of the Alzheimer’s disease-associated amyloid β-protein by promoting microglial phagocytosis C Zhang, A Griciuc, E Hudry, Y Wan, L Quinti, J Ward, AM Forte, X Shen, ... Scientific reports 8 (1), 1144, 2018 | 85 | 2018 |
| Inactivation of VCP/ter94 Suppresses Retinal Pathology Caused by Misfolded Rhodopsin in Drosophila A Griciuc, L Aron, MJ Roux, R Klein, A Giangrande, M Ueffing PLoS genetics 6 (8), e1001075, 2010 | 82 | 2010 |
| ER stress in retinal degeneration: a target for rational therapy? A Griciuc, L Aron, M Ueffing Trends in molecular medicine 17 (8), 442-451, 2011 | 65 | 2011 |
| Clearance of RhodopsinP23H aggregates requires the ERAD effector VCP A Griciuc, L Aron, G Piccoli, M Ueffing Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1803 (3), 424-434, 2010 | 55 | 2010 |
| Cromolyn sodium delays disease onset and is neuroprotective in the SOD1G93A Mouse Model of amyotrophic lateral sclerosis EJ Granucci, A Griciuc, KA Mueller, AN Mills, H Le, AM Dios, D McGinty, ... Scientific Reports 9 (1), 17728, 2019 | 42 | 2019 |
| Proteomic survey reveals altered energetic patterns and metabolic failure prior to retinal degeneration A Griciuc, MJ Roux, J Merl, A Giangrande, SM Hauck, L Aron, M Ueffing Journal of Neuroscience 34 (8), 2797-2812, 2014 | 34 | 2014 |
| Retinal degenerative diseases MM LaVail, J Ash, RE Anderson, JG Hollyfield, C Grimm Springer Science & Business Media, 2011 | 18 | 2011 |
| Gene therapy for CNS disorders: modalities, delivery and translational challenges J Gao, S Gunasekar, Z Xia, K Shalin, C Jiang, H Chen, D Lee, S Lee, ... Nature Reviews Neuroscience, 1-20, 2024 | 15 | 2024 |
| Evaluation of bumetanide as a potential therapeutic agent for Alzheimer’s disease B Boyarko, S Podvin, B Greenberg, JD Momper, Y Huang, WH Gerwick, ... Frontiers in Pharmacology 14, 1190402, 2023 | 13 | 2023 |
| Evaluation of fluorinated cromolyn derivatives as potential therapeutics for Alzheimer’s disease TM Shoup, A Griciuc, MD Normandin, L Quinti, LV Walsh, M Dhaynaut, ... Journal of Alzheimer's Disease 80 (2), 775-786, 2021 | 10 | 2021 |
| Natural medicine HLXL targets multiple pathways of amyloid-mediated neuroinflammation and immune response in treating alzheimer's disease Y Liang, DYW Lee, S Zhen, H Sun, B Zhu, J Liu, D Lei, CCJ Lin, S Zhang, ... Phytomedicine 104, 154158, 2022 | 8 | 2022 |
| Looking into Eyes: Rhodopsin Pathologies in Drosophila A Griciuc, L Aron, M Ueffing Retinal Degenerative Diseases, 415-423, 2011 | 4 | 2011 |
| Prophylaxis and treatment of a neurodegenerative disease not based on a protein-folding disorder M Ueffing, B Arango-Gonzalez, A Griciuc US Patent 11,229,651, 2022 | 3 | 2022 |
| Fluorinated Cromolyn Derivatives for Potential Alzheimer’s Disease Treatment T Shoup, M Normandin, K Takahashi, A Griciuc, M Dhaynaut, L Quinti, ... Journal of Nuclear Medicine 60 (supplement 1), 114-114, 2019 | 3 | 2019 |
| Methods and agents for treating Alzheimer's disease RE Tanzi, A Griciuc US Patent 9,937,231, 2018 | 3 | 2018 |
